aTYR PHARMA (ATYR) Change in Acquisitions & Divestments (2014 - 2026)

aTYR PHARMA (ATYR) has reported Change in Acquisitions & Divestments for 13 consecutive years, with $23.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Acquisitions & Divestments rose 8.89% year-over-year to $23.4 million; the trailing twelve-month figure through Jun 2026 stood at $89.2 million (up 10.07% YoY), and the FY2025 full-year result was $88.5 million, up 2.39% from the prior year.
• Change in Acquisitions & Divestments improved to $23.4 million in Q2 2026 per ATYR's latest filing, from $17.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $33.6 million in Q3 2023 and bottomed at $9.3 million in Q1 2023.
• Historically, Change in Acquisitions & Divestments has averaged $22.1 million across 5 years, with a median of $21.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Acquisitions & Divestments jumped 530.43% in 2022, then slumped 37.79% in 2024.
• Over 5 years, Change in Acquisitions & Divestments stood at $28.1 million in 2022, then fell by 2.18% to $27.5 million in 2023, then dropped by 27.27% to $20.0 million in 2024, then surged by 46.54% to $29.3 million in 2025, then retreated by 20.25% to $23.4 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $23.4 million, $17.5 million, and $29.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.